A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of HuL001 in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

HuniLife Biotechnology, Inc.1 个研究点分布在 1 个国家目标入组 21 人开始时间: 2025年8月18日最近更新: 2025年10月7日

干预措施

试验速览

阶段: 1 期
状态: Enrolling By Invitation
发起方: HuniLife Biotechnology, Inc.
入组人数: 21
试验地点: 1
主要终点: Myeloma responses

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The goal of this clinical trial is to learn if the antibody drug HuL001, combined with

Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients. It will also learn about the safety and tolerability of the therapeutic combination. The objectives of this study are:

To evaluate the safety and tolerability of HuL001 (in combination with Len/Dex).
To evaluate the efficacy of HuL001 (in combination with Len/Dex).

Researchers will use the antibody drug HuL001, combined with Len/Dex, to see if this works for Multiple Myeloma therapy.

Participants will:

Receive HuL001 antibody injections every 2 weeks
Take Lenalidomide for 21 consecutive days each month
Take Dexamethasone every 1 week
Visit the clinic on scheduled days for checkups and tests
Keep a diary of their symptoms and Myeloma responses.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects who meet ALL inclusion criteria will be included.
•Subjects aged 18 (inclusive) or older.
•Confirmed diagnosis of RRMM according to the IMWG guidelines (International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, 2016).
•Subjects must have one or more of the following measurable disease criteria:
•Serum M-protein level ≥ 0.5 g/dL.
•Urine M-protein level ≥ 200 mg/24 hours.
•Light chain MM without measurable M-protein in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL (local lab) and abnormal serum immunoglobulin kappa lambda free light chain ratio (per normal ranges of local lab).
•Subjects have disease progression on, refractory to, or intolerant to at least 3 prior lines of anti-myeloma therapies or 2 prior lines of therapies with three different drugs, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug, and are refractory to at least one of these drugs, or who are unwilling to receive or ineligible for other standard therapies according to local medical practice.
•There must be a time interval ≥ 3 months between the prior hematopoietic cell transplantation (HCT, counted as 1 prior line of therapy) and the first dose of HuL
•All toxicities associated with the prior anti-myeloma therapy have recovered to Grade 1 or baseline at the screening.
•Eastern Cooperative Oncology Group (ECOG) performance score of 0-
•Life expectancy ≥ 6 months in the opinion of the investigator.
•Adequate organ functions are defined as follows.
•Hemoglobin ≥ 8.5 g/dL.
•White blood cell (WBC) count ≥ 2.5 x 103/μL.
•Neutrophil count ≥ 1.5 × 103/μL.
•Platelet count ≥ 80 × 103/μL.
•Aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN).
•Alanine aminotransferase (ALT) ≤ 2.5 × ULN.
•Total bilirubin ≤ 2 × ULN.
•Creatinine clearance (CrCl) ≥ 60 mL/min, calculated using Cockcroft-Gault formula.
•Subjects receiving hematopoietic growth factor support, e.g., erythropoietin, granulocyte-colony stimulating factor, platelet stimulator, etc. must have a 2-week interval between growth factor support and the screening evaluation. They may receive growth factor support after the DLT assessment period during the study.
•There must be at least a 2-week interval between the last red blood cell (RBC) transfusion and hemoglobin assessment at the screening and at least a 1-week interval between the last platelet transfusion and the platelet assessment at the screening. Subjects may receive RBC and platelet transfusion after the DLT assessment period during the study.
•Negative serology test for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) infection. Note: If a subject with positive anti-HCV Ab, the subject must be with negative HCV RNA for enrollment. If a subject with positive HBsAg, the subject must be with undetectable HBV DNA for enrollment.
•Female subject with reproductive potential must have a negative result of serum pregnancy test at the screening visit and urine pregnancy test before each cycle of HuL001 administration.
•Female subject with reproductive potential and male subject with reproductive potential must agree to refrain from unprotected sex and use 2 methods of highly effective contraception with their partner (e.g., barrier contraceptives [male condom, female condom, or diaphragm plus spermicide], intrauterine device, hormonal methods [hormone shot or injection, implants, combination oral contraceptives, or patches]) for ≥ 6 months after the last dose of HuL
•Physically and mentally capable of participating in the study and willing to adhere to study procedures.
•Provision of signed informed consent.

排除标准

•Subjects who meet ANY exclusion criteria will be excluded.
•Suspected or known contraindication or intolerant reaction to lenalidomide and/or dexamethasone.
•Suspected or known hypersensitivity (including allergy) to any of the components of the HuL001, lenalidomide, or dexamethasone.
•Previous history of anaphylaxis and severe allergic reaction, generation of neutralizing antibodies, or hypersensitivity to albumin or a protein-based therapeutic, or any other mAb.
•Planning to receive the HCT during the study period (approximately 6 months following the first dose of HuL001).
•Active graft versus host diseases (GvHD) following the prior HCT.
•Will be on digoxin therapy throughout the study period.
•Presence of multiple primary cancers with the exception of carcinoma in situ and skin cancers after curative surgery.
•Central nervous system (CNS) or meningeal involvement of MM by clinical signs or imaging studies.
•Significant infections requiring systemic treatment within 1 month prior to the first dose of HuL
•History of active tuberculosis in line with local medical practice.
•Major surgery within 4 weeks prior to the first dose of HuL
•Subjects should be fully recovered from any surgically related complications.
•Receipt of radiation therapy or systemic anti-MM treatments within 2 weeks prior to the first dose of HuL
•Receipt of any live or live attenuated vaccine (e.g., varicella, pneumococcus) within 4 weeks prior to the first dose of HuL001 or planning to receive live vaccine during the study period. Seasonal flu and COVID-19 vaccines not containing live virus are permitted.
•Any known active gastrointestinal dysfunction interfering with subject's ability to swallow tablets or any known active gastrointestinal dysfunction that could interfere with absorption of study drugs as judged by the investigator.
•Myocardial infarction, unstable angina, or poorly controlled arrhythmia within 6 months prior to the screening visit.
•Evidence or history of severe intercurrent medical conditions or clinically significant comorbidities that may interfere with optimal participation in the study or place the subject at increased risk of adverse events, including but not limited to psychiatric, ophthalmic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunologic, metabolic, urologic, dermatologic, neurologic, or allergic diseases, or other significant clinical findings within 3 months prior to the screening, as judged by the Investigator.
•Receipt of any investigational drug or device or participation in a clinical study within 28 days prior to the V2(C1D1).
•History of substance or alcohol abuse within 6 months prior to the screening visit.
•Female subjects who are pregnant, breastfeeding, or planning to be pregnant or breastfeeding during the screening and study period.
•Subject who is considered unfit to participate in the clinical study as assessed by the investigator.